Neuphoria Therapeutics
NEUP
9 hedge funds and large institutions have $2.06M invested in Neuphoria Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.01% → 0.01% (-0.01%)
18% less funds holding
Funds holding: 11 → 9 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
68% less capital invested
Capital invested by funds: $6.52M → $2.06M (-$4.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$452K |
| 2 |
Two Sigma Investments
New York
|
+$74.4K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$28.1K |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$20.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.89M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$786K |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$454K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$128K |
| 5 |
VF
Virtu Financial
New York
|
-$45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
1
Lynx1 Capital Management
San Juan,
Puerto Rico
| $1.22M | +$20.9K | +733 | +1% |
|
|
2
Point72 Asset Management
Stamford,
Connecticut
| $490K | -$786K | -27,553 | -50% |
|
|
3
Morgan Stanley
New York
| $281K | +$452K | +15,828 | New |
|
|
4
Two Sigma Investments
New York
| $46.3K | +$74.4K | +2,606 | New |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $17.8K | +$28.1K | +986 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.38K | +$3.68K | +129 | +2,580% |
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $757 | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $487 | -$5.14K | -180 | -87% |
|
|
APC
9
Aspire Private Capital
Cornelius,
North Carolina
| $296 | – | – | – |
|
|
TCM
10
Tang Capital Management
San Diego,
California
| – | -$1.89M | -58,333 | Closed |
|
|
OCA
11
Octagon Capital Advisors
New York
| – | -$454K | -14,000 | Closed |
|
|
BI
12
BVF Inc
San Francisco,
California
| – | -$128K | -3,948 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$45K | -1,380 | Closed |
|
|
FIA
14
FNY Investment Advisers
New York
| – | -$5K | -177 | Closed |
|
NEUP Hedge Fund Activity: Q4 2023 in Review
9 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q4 2023, worth a combined $2.06M — down 68% from $6.52M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NEUP and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $452K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.89M sold.
- 9 institutional investors held Neuphoria Therapeutics (NEUP) as of Q4 2023, down from 11 in Q3 2023.
- Funds reported $2.06M of Neuphoria Therapeutics stock for Q4 2023, down 68% quarter-over-quarter.
- 3 funds opened new Neuphoria Therapeutics positions in Q4 2023 and 5 closed out, a net change of -2 holders.
- The largest Neuphoria Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $452K added.
- The largest Neuphoria Therapeutics seller in Q4 2023 was Tang Capital Management, an estimated $1.89M sold.
Based on aggregated 13F filings for Q4 2023.